Last reviewed · How we verify
Anlotinib hydrochloride capsule + TQB2450 injection
Anlotinib is a multi-target tyrosine kinase inhibitor combined with TQB2450, a PD-L1 inhibitor, to block tumor angiogenesis and enhance anti-tumor immune response.
Anlotinib is a multi-target tyrosine kinase inhibitor combined with TQB2450, a PD-L1 inhibitor, to block tumor angiogenesis and enhance anti-tumor immune response. Used for Advanced non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).
At a glance
| Generic name | Anlotinib hydrochloride capsule + TQB2450 injection |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Multi-target tyrosine kinase inhibitor + PD-L1 inhibitor combination |
| Target | VEGFR, FGFR, PDGFR, c-Kit (anlotinib); PD-L1 (TQB2450) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Anlotinib inhibits multiple receptor tyrosine kinases (VEGFR, FGFR, PDGFR, c-Kit) to suppress tumor neovascularization and growth. TQB2450 is a humanized monoclonal antibody targeting PD-L1 that blocks the PD-1/PD-L1 immune checkpoint, allowing T cells to recognize and attack cancer cells. The combination leverages both anti-angiogenic and immunotherapeutic mechanisms.
Approved indications
- Advanced non-small cell lung cancer
- Other solid tumors (under investigation in Phase 3)
Common side effects
- Hypertension
- Proteinuria
- Hand-foot skin reaction
- Fatigue
- Immune-related adverse events (from PD-L1 inhibitor)
Key clinical trials
- Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. (PHASE2)
- A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer (PHASE2)
- A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer (PHASE3)
- A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients (PHASE3)
- Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer (PHASE3)
- Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA (PHASE2)
- A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy (PHASE1)
- A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: